Home
HelpTest ID BLOD0849 Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum
Useful For
Prenatal screening for open neural tube defect
Specimen Type
SerumNecessary Information
In order to provide the best results, either answer the order entry questions or provide the required information using the Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595).
Specimen Required
Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Do not collect specimen after amniocentesis as this could affect results.
2. Centrifuge and aliquot serum into plastic vial within 2 hours of collection.
Additional Information:
1. Collect blood between 15 weeks, 0 days and 22 weeks, 6 days.
2. Initial or repeat testing is determined in the laboratory at the time of report and will be reported accordingly. To be considered a repeat test for the patient, the testing must be within the same pregnancy and trimester, with interpretable results for the same test, and both tests are performed at Mayo Clinic.
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | OK |
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 14 days | |
| Frozen | 90 days | ||
| Ambient | 7 days |
Day(s) Performed
Monday through Friday
Report Available
4 to 6 daysMethod Name
Two-Site Immunoenzymatic (Sandwich) Assay
Performing Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
82105
Reporting Name
AFP Single Marker SCRN, Maternal, SReference Values
NEURAL TUBE DEFECTS:
An alpha-fetoprotein (AFP) multiple of the median (MoM) <2.5 is reported as screen negative.
AFP MoM ≥2.5 (singleton and twin pregnancies) are reported as screen positive.
An interpretive report will be provided.
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.Forms
1. Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595) is required
2. If not ordering electronically, complete, print, and send a General Request (T239)
Special Instructions
Secondary ID
113382SANFORD LABORATORY INTERFACE BUILD INFORMATION
| Result Code | Result Code Description |
|---|---|
| 17111 | Recalculated Maternal Serum Screen |
| 22806 | Results Summary |
| 22807 | Neural Tube Defect Risk Estimate |
| 17134 | AFP |
| 22808 | AFP MOM |
| 17141 | Interpretation |
| 17143 | Recommended Follow Up |
| 17142 | Additional Comments |
| 17112 | Collection Date |
| 17113 | Birthdate |
| 17114 | Calculated Age at EDD |
| 17115 | Maternal Weight |
| 17116 | Maternal Weight |
| 17117 | Insulin Dependent Diabetes |
| 22813 | Patient Race |
| 22814 | Current Cigarette Smoking Status |
| 17123 | EDD by U/S Scan |
| 17130 | GA on Collection by U/S Scan |
| 17125 | EDD by LMP |
| 17131 | GA on Collection by Dates |
| 17133 | GA Used in Risk Estimate |
| 17119 | Number of Fetuses |
| 22815 | Number of Chorions |
| 17120 | IVF Pregnancy |
| 22817 | Prev Pregnancy W/ Neural Tube Defect |
| 22818 | Patient or Father of Baby has NTD |
| 22819 | Initial or Repeat Testing |
| 22820 | Physician Phone Number |
| 17144 | General Test Information |